Please assess the completion status of the following clinical trial:

Trial Title: Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Age ≥ 18 years~* Breast cancer patients suffering from chemotherapy-induced peripheral neuropathy for at least 3 months after the end of their last cancer chemotherapy~* Numerical rating scale ≥ 4~* Patient in stable clinical situation on the next month (no surgery, radiotherapy, hormone therapy, chemotherapy or other treatment scheduled in the month following the enrollment)~* Patients affiliated to the French Social Security~* Patients with free and informed consent has been obtained~Exclusion Criteria:~* - Hypersensitivity to the active substance or to any of the excipients~* Hypertension~* History of stroke~* Severe heart failure~* Severe hepatic impairment~* Shortness of breath~* Congenital galactosemia, glucose-galactose malabsorption, lactase deficiency~* Association with linezolid~* Pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy~* Diabetes (type I and II)~* Medical and surgical history incompatible with the study~* Patient receiving treatment with amantadine, ketamine, memantine, L-Dopa, dopaminergic agonists, anticholinergics, barbiturates, neuroleptics, Monoamine oxidase inhibitor, dantrolene or baclofen, phenytoin, cimetidine, ranitidine, procainamide, quinidine, quinine, amiodarone, fluoxetine, paroxetine, propafenone, thioridazine, ritonavir, nicotine, hydrochlorothiazide, warfarin~* Present or past psychotropic substances and alcohol dependence~* Childbearing age, no use of effective contraceptive method, pregnancy or lactation~* Patient exclusion period, or the total allowable compensation exceeded~* Patients undergoing a measure of legal protection (guardianship, supervision ...)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dextromethorphan (Type: EXPERIMENTAL): The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
- placebo (Type: PLACEBO_COMPARATOR): The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

Based on this trial design, predict the completion outcome and termination type (if applicable).